Clinical phenotype and prognosis of patients with diabetic kidney disease complicated by a primary podocytopathy
Nephrology Dialysis Transplantation · 30.09.2026 · 41 (10) · 1828-1838
DOI: 10.1093/ndt/gfag050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 12.03.2026. Verfasst von Yue Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Podocytes, Kidney Failure, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Fund.
Abstract (Originalsprache)
Background
Diabetic nephropathy (DN), a leading cause of end-stage kidney disease (ESKD), often progresses despite standard care. Evidence suggests a DN subgroup exhibiting overlapping features of primary podocytopathy, potentially responsive to immunosuppression, that has not yet been systematically studied. We hypothesized that DN patients with biopsy-proven concurrent ultrastructural features of primary podocytopathy will demonstrate superior renal outcomes following immunosuppressive therapy, compared with those with isolated DN pathology.
Methods
A retrospective analysis was conducted on 88 patients with biopsy-confirmed DN recruited from Peking University First Hospital between 2017 and 2022. The patients were categorized into two groups: Group A (patients with DN and primary podocytopathy) and Group B (patients with DN without primary podocytopathy). Seven patients with diabetes and primary podocytopathy but without DN served as disease controls. Primary podocytopathy was defined by electron microscopy foot process width (FPW) ≥821 nm.
Results
Patients in Group A had a shorter duration of nephropathy (P = .005), lower serum albumin levels (P < .001) and higher proteinuria (P = .032) than those in Group B. Light microscopy demonstrated milder glomerular lesions in Group A (P < .001), with most cases classified as Class I or II (63.6%). Electron microscopy showed significantly broader FPW in Group A than in Group B (1310.5 ± 510.1 nm vs 569.1 ± 97.5 nm, P < .001). While Group B showed no such benefit and differed significantly from the control group, patients in Group A benefited from immunosuppressive therapy, with a significantly reduced risk of ESKD.
Conclusion
DN with concurrent primary podocytopathy represents a distinct clinical entity characterized by nephrotic-range proteinuria, ultrastructural podocyte effacement and favorable response to immunosuppressive therapy. Early renal biopsy incorporating FPW assessment enables targeted therapy to mitigate ESKD progression in this high-risk phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Renal Division, Peking University First Hospital, Beijing, China.
- Division of Nephrology, Peking University Shenzhen Hospital, Shenzhen, China.
- Department of Pathology, School of Basic Medical Sciences Peking University Third Hospital, Peking University Health Science Center; Beijing, China.
- Laboratory of Electron Microscopy, Pathological Center, Peking University First Hospital, Beijing, China.
Förderung
- National Natural Science Fund
Zitieren
APA
Zhou, Y., Wang, H., Nie, L., Zhao, M. H., & Wang, S. X. (2026). Clinical phenotype and prognosis of patients with diabetic kidney disease complicated by a primary podocytopathy. Nephrology Dialysis Transplantation, 41(10), 1828-1838. https://doi.org/10.1093/ndt/gfag050
Vancouver
Zhou Y, Wang H, Nie L, Zhao MH, Wang SX. Clinical phenotype and prognosis of patients with diabetic kidney disease complicated by a primary podocytopathy. Nephrology Dialysis Transplantation. 2026;41(10):1828-1838. doi:10.1093/ndt/gfag050
BibTeX
@article{Zhou2026,
author = {Zhou, Yue and Wang, Hui and Nie, Lin and Zhao, Ming-Hui and Wang, Su-Xia},
title = {Clinical phenotype and prognosis of patients with diabetic kidney disease complicated by a primary podocytopathy},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
volume = {41},
number = {10},
pages = {1828--1838},
doi = {10.1093/ndt/gfag050}
}
EUVIMED